Skip to main content

Table 1 Characteristics of included systematic reviews

From: Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults – a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing

Source

Type of study

Includes AF-studies

N

AF-patients

N

Mean age in years

Intervention

Comparator

mean Follow-Up in years

Relevant outcomes

AS

IS

HS

M

MB

IB

GB

MI

Adam et al. 2012 [31]

MA

3

50,578

>70

NOACs (dabigatran, apixaban, rivaroxaban)

Warfarin

≈ 2

 

X

X

X

    

Agarwal et al. 2012 [27]

MA

8

32,053

70–81.5

subgroup ≥75

Warfarin

Other thrombophylaxis (Aspirin, Aspirin + clopidogrel, Ximelagatran, Dabigatran, Rivaroxaban, Apixaban, Indraparinux)

1.74a

X

       

Aguilar et al. 2005 [34]

CR + MA

5

2313

69

Warfarin

Placebo/control

1.5

X

X

 

X

X

X

 

X

Aguilar et al. 2007 [44]

MA

8

9598

71

Warfarin, acenocumarol

PAI (ASA, ASA + clopidogrel, triflusal)

1.9

X

X

 

X

X

X

 

X

Andersen et al. 2008 [37]

MA

15

16,058

63.3–81.5

warfarin

Placebo, antiplatelets, low dose warfarin, low-dose warfarin + aspirin

1.7

    

X

   

Assiri et al. 2013 [42]

MTM

21

80,906

71

Pair-wise comparison of aspirin, aspirin + clopidogrel, warfarin, apixaban, dabigatran, edoxaban, rivaroxaban and placebo

1.85a

X

  

X

X

X

  

Baker et al. 2012 [53]

MA

4

44,733

69–73

NOACs (dabigatran, apixaban, rivaroxaban)

Warfarin indirect comparison of NOACs

1.8–2.0

X

X

X

X

X

 

X

 

Briceno 2015 [29]

MA

7

73,978

70–74

NOACs (dabigatran, rivaroxaban, apixaban, edoxaban)

DEVICE (Watchman left atrial occlusion device)

Warfarin

1–2.8

X

  

X

X

   

Cameron et al. 2014 [46]

MTM

16

82,314

62–83

VKA

NOACs

ASA

12 weeks −3.5 years

X

   

X

   

Capodanno et al. 2013 [47]

MA

3

50,578

71.3

NOACs (dabigatran, apixaban, rivaroxaban)

Warfarin

1.9

X

X

X

X

X

X

X

X

Chatterje et al. 2013 [63]

MA, MTM

6

57,491

69.3–73

NOACs (dabigatran, apixaban, rivaroxaban)

Warfarin, ASA

0.23–2.0

     

X

  

Coleman et al. 2012 [35]

MA

16

42,983

69.5

Pair-wise comparisons of warfarin (adjusted + low dose), PAI, ximelagatran, dabigatran, placebo/control

2

      

X

 

Cooper et al. 2006 [41]

MTM

19

17,833

68.3

Pair-wise comparison of warfarin (adjusted + low dose), ASA, indobufen, ximelagtran, placebo/control

1.8

 

X

  

X

   

Dogliotti et al. 2013 [48]

MA

5

51,895

71.4

NOACs (dabigatran, apixaban, rivaroxaban, ximelagatran)

Warfarin

1.75

X

X

X

X

X

   

Dogliotti et al. 2014 [40]

MTM

20

79,808

68.2

Pair-wise comparison of ASA, ASA plus clopidogrel, VKA, dabigatran, rivaroxaban, apixaban or placebo/control

>1

X

X

 

X

X

   

Harenberg et al. 2012 [70]

MTM

3

50,578

70–73

NOACs (dabigatran, apixaban, rivaroxaban)

Warfarin

1.88

 

X

 

X

X

X

 

X

Hart et al. 1999 [4]

MA

6

9874

70

Adjusted-dose warfarin, PAI

Other Antithrombotic regimens placebo

ASA

Mean FU 1.7 y1.7ears, ranged from 1.2 to 2.3

X

X

 

X

X

X

  

Hart et al. 2007 [39]

MA

29

28,044

71

Adjusted-dose warfarin,

PAI

Placebo/No Treatment

1.5

X

X

 

X

X

X

  

Holster 2013 [33]

MA

8

151,578

65–73

NOACs (apixaban, edoxaban, rivaroxaban, dabigatran)

Warfarin

12 weeks – 2 years

    

X

 

X

 

Jia 2014 [54]

MA

5

72,961

70–73

NOACs (apixaban, edoxaban, rivaroxaban, dabigatran)

Warfarin

1.6–2.8

X

X

X

X

X

X

X

X

Lega 2014 [30]

MA

3

50,578

70–73

NOACs (apixaban,rivaroxaban, dabigatran)

Warfarin

1.8–2

X

   

X

   

Liew et al. 2014 [49]

MA

4

71,683

no mean

NOACs (dabigatran, apixaban, rivaroxaban, edoxaban)

Warfarin

1.8–2.8

   

X

 

X

  

Lin 2015 [43]

MTM

49

897,748

71

Warfarin

ASA, dabigatran, rivaroxaban, apixaban, edoxaban, no treatment

12 weeks −3.6 years

X

X

 

X

X

X

X

 

Lip et al. 2006 [36]

MA

13

14,423

68.4

Adjusted-dose warfarin

ASA

fixed low-dose warfarin, placebo, ximelagatran

2.13

 

X

 

X

X

   

Miller et al. 2012 [50]

MA

3

44,563

71.5

NOACs (dabigatran, apixaban, rivaroxaban)

Warfarin

1.91

X

X

X

X

X

X

X

X

Providência et al. 2014 [51]

MA

7

80,290

71.3

NOACs (dabigatran, apixaban, rivaroxaban, ximelagatran, edoxaban)

Warfarin

1.96

X

X

 

X

X

X

X

X

Rong 2015 [66]

MA

4

71,683

70–73

NOACs (apixaban, edoxaban, rivaroxaban, dabigatran)

Warfarin

1.8–2.8

    

X

X

X

 

Roskell et al. 2010 [67]

MTM

26

not stated

71.2

dabigatran

Indirect comparison: Placebo, ASA, ASA + clopidgrel, adj. Dose VKA

1.87

X

X

 

X

X

X

 

X

Ruff et al. 2014 [87]

MA

4

71,683

71.4

NOACs (dabigatran, apixaban, rivaroxaban, edoxaban)

Warfarin

2

X

X

X

X

X

X

X

X

Sardar et al. 2013 [64]

MA

3

50,578

70.6

NOACs (dabigatran, apixaban, rivaroxaban)

Warfarin

1.88

X

 

X

X

X

X

X

-

Sardar et al. 2014 [32]

MA

4

11,562

subgroup for ≥75

NOACs (dabigatran, apixaban, rivaroxaban)

Warfarin, ASA

1.1–2.0

X

   

X

   

Schneeweiss et al. 2012 [69]

MTM

3

44,535

70–73

NOACs (dabigatran, apixaban, rivaroxaban)

Warfarin

1.8–2.0

X

   

X

   

Segal et al. 2000 [38]

MA

11

8690

66–80

VKA

ASA

ASA + low dose warfarin placebo

0.3–2.6

X

  

X

X

   

Senoo 2015 [65]

MA

3

1940

70–73

NOAC (rivaroxaban, apixaban, dabigatran)

Warfarin

1.3–2.0

X

   

X

X

X

 

Sharma et al. 2015 [26]

(Subgroup >75 with AF)

MA

5

27,622

>75

Single NOACs (dabigatran, apixaban, rivaroxaban, edoxaban)

Warfarin

1.75

X

  

X

    

Taylor et al. 2001 [45]

 

5

3298

73

Warfarin

PAI

2.35

X

  

X

X

  

X

Testa et al. 2012 [52]

MA

3

50,578

71.5

NOACs (dabigatran, apixaban, rivaroxaban)

Warfarin

>1

X

X

X

X

X

  

X

Verdecchia et al. 2015 [68]

MTM

4

71,683

71.5

Indirect comparison (dabigatran, apixaban, rivaroxaban, edoxaban)

Dose-adjusted warfarin

2.15

X

X

 

X

X

X

X

X

  1. AS All stroke, CR Cochrane Review, GB Gastrointestinal Bleeding, HS Haemorrhagic Stroke, IB Intracranial Bleeding, IS Ischemic stroke, M Mortality, MA Meta-analysis, MB Major Bleeding, MI Myocardial infarction, MA Meta-analysis, NMA network meta-analysis
  2. a Calculated by the review team
Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us